Intellectual Property (Patents)

Diamond v. Chakrabarty — Study Notes

Diamond v. Chakrabarty, 447 U.S. 303 (1980)

Study notes for Diamond v. Chakrabarty: professor notes, cold call prep, exam angles, and memory aids.

A live, human-made microorganism is patentable as a nonnaturally occurring 'manufacture' or 'composition of matter' under § 101.
Professor Notes

In Diamond v. Chakrabarty, the Supreme Court addressed the complex issue of whether genetically engineered living organisms could be patented under U.S. patent law. The case highlights a significant shift in the interpretation of what constitutes 'patentable subject matter' under 35 U.S.C. § 101. Professors often emphasize the implications of this ruling not just for biotechnology, but for the evolution of patent law in a modern context, where advancements in genetics and synthetic biology raise ongoing questions about the boundaries of patentability. The Supreme Court's affirmation suggests that the legal criterion for patentability accommodates innovative scientific deviations from natural phenomena, underlining a conceptual move towards recognizing human ingenuity in creating new and useful inventions.

Cold Call Prep
  1. 1Explain the significance of the term 'manufacture' as it relates to the case.
  2. 2What were the primary legal precedents that influenced the Court's decision?
  3. 3Describe how Chakrabarty's invention differs from naturally occurring microorganisms.
  4. 4How does this case impact future biotechnology patent applications?
  5. 5Discuss the implications of the ruling for ethical considerations in patent law.
Mnemonic Device

GEM: Genetically Engineered Microbe.

Distinguish From
CaseDistinction
Association for Molecular Pathology v. Myriad GeneticsMyriad held that naturally occurring genes could not be patented, whereas Chakrabarty established that human-made microorganisms can be.
Bilski v. KapposBilski focused on abstract ideas not being patentable, whereas Chakrabarty reinforced the patentability of tangible, human-made innovations.
Policy Arguments

For the Rule

Allowing patents on genetically engineered organisms encourages innovation in biotechnology, promoting public benefits such as environmental recovery and health advancements.

Against the Rule

Granting patents on living organisms raises ethical concerns, including the commodification of life and potential risks of monopolization in essential biological resources.

Class Discussion Points
  • The balance between ethical implications and innovation in biotechnology patents.
  • The impact of Chakrabarty on the biotechnology industry and environmental applications.
  • How the definition of 'manufacture' can evolve with technological advancements.
Exam Angle

This case frequently appears in patent law exams, often focusing on the interpretation of § 101 and its implications for patenting living organisms, as well as broader questions related to innovation and technology transfer.

Ace Your Cold Calls with Briefly

Get AI-powered case briefs, study notes, and cold call prep for every case in your casebook.